In a study by Velazquez et al., patients with coronary artery disease and left ventricular dysfunction were assigned to either medical therapy alone or medical therapy plus CABG. At 5 years, there was no significant difference between the two study groups in the rate of death from any cause.
The role of coronary-artery bypass grafting (CABG) in patients with coronary artery disease and heart failure has not been clearly established.
• Approximately how many people in the United States and Europe have heart failure?
An estimated 5.8 million patients in the United States and 15 million in Europe have heart failure.
• What disease is the most common cause of heart failure in industrialized nations?
Coronary artery disease is the most common substrate for heart failure in industrialized nations.
Table 2. Study Outcomes.
Morning Report Questions
Q: Did CABG provide a survival advantage to subjects in this study?
A: There was no statistically significant difference between the two study arms for the primary end point of all-cause mortality.
Q: Did any outcome differ between the study groups?
A: Patients assigned to CABG had lower rates of cardiovascular death and death or cardiovascular hospitalization than those assigned to medical therapy.